Pharsight

Selzentry patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6667314

(Pediatric)

VIIV HLTHCARE Tropane derivatives useful in therapy
Feb, 2022

(1 year, 7 months ago)

US7368460 VIIV HLTHCARE Tropane derivatives useful in therapy
Nov, 2022

(9 months ago)

US7368460

(Pediatric)

VIIV HLTHCARE Tropane derivatives useful in therapy
May, 2023

(3 months ago)

Selzentry is owned by Viiv Hlthcare.

Selzentry contains Maraviroc.

Selzentry has a total of 3 drug patents out of which 3 drug patents have expired.

Expired drug patents of Selzentry are:

  • US6667314*PED
  • US7368460
  • US7368460*PED

Selzentry was authorised for market use on 04 November, 2016.

Selzentry is available in solution;oral dosage forms.

Selzentry can be used as method of treating patients infected with ccr5-tropic hiv-1.

The generics of Selzentry are possible to be released after 30 April, 2024.

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Oct 30, 2023
Pediatric Exclusivity (PED) Apr 30, 2024

Drugs and Companies using MARAVIROC ingredient

Market Authorisation Date: 04 November, 2016

Treatment: Method of treating patients infected with ccr5-tropic hiv-1

Dosage: SOLUTION;ORAL

How can I launch a generic of SELZENTRY before it's drug patent expiration?
More Information on Dosage

SELZENTRY family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic